Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 28, 2014; 20(28): 9253-9260
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9253
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9253
Table 1 Current stage of development of direct antiviral agents
| Inhibitors of the NS3/4A serine protease | |
| First-generation | |
| Boceprevir | Approved |
| Telaprevir | Approved |
| Faldaprevir | Active clinical development |
| Sovaprevir | Active clinical development |
| Asunaprevir | Active clinical development |
| Simeprevir | Active clinical development |
| Danoprevir | Active clinical development |
| Vaniprevir | Active clinical development |
| Second-generation | |
| MK-5172 | Active clinical development |
| NS5A inhibitors | |
| Daclatasvir | Advanced clinical development |
| GS-5885 | Active clinical development |
| ABT-267 | Active clinical development |
| PPI-461 | Active clinical development |
| MK-8762 | Active clinical development |
| NS5B polymerase inhibitors | |
| Nucleos(t)ide inhibitors | |
| Sofosbuvir | Advanced clinical development |
| Mericitabine | Active clinical development |
| ALS-2200 | Active clinical development |
| Non-nucleos(t)ide inhibitors | |
| Setrobuvir | Active clinical development |
| ABT-333 | Active clinical development |
| GSK625433 | Active clinical development |
Table 2 Available data from the studies in extenso on the use of direct-acting antiviral agents in the post-liver transplantation setting
| Pungpapong et al[44] | Coilly et al[45] | Werner et al[46] | Werner et al[48] | |
| Patients (n) | 60 | 37 | 9 | 14 |
| Baseline characteristics | ||||
| Regimen (n) | ||||
| TLV | 35 | 19 | 9 | 14 |
| BCV | 25 | 18 | 0 | 0 |
| Four-week lead-in phase | 100% | 100% | 0% | 0% |
| IS therapy (n) | ||||
| TAC | 3 | 15 | 4 | 6 |
| CSA | 65 | 22 | 4 | 6 |
| SIR | 1 | 0 | 1 | 2 |
| Fibrosis stage (n) | ||||
| FO-F2 | 31 | 20 | 6 | 7 |
| F3-F4 | 38 | 17 | 3 | 7 |
| Cholestatic hepatitis (n) | NA | 6 | 1 | NA |
| Results | ||||
| HCV-RNA negative | ||||
| Week 4 | NA | 51% (19/37) | 44% (4/9) | 43% (6/14) |
| Week 8 | NA | NA | NA | NA |
| Week 12 | 91% (55/60) | 73% (27/37) | 89% (8/9) | 71% (10/14) |
| Week 24 | 56% (24/43) | NA | NA | 57% (8/14) |
| Week 48 | NA | 61% (17/28) | NA | 50% (7/14) |
| Adverse events | ||||
| Hematological AEs | ||||
| Anemia | 93% | 92% | 66% | 71% |
| Leukopenia | 77% | 40% | 22% | 36% |
| Thrombocytopenia | 12% | 32% | 44% | 64% |
| Infectious complication | 12% | 27% | 11% | 14% |
| Renal insufficiency | 38% | 13% | 11% | 7% |
| Acute rejection | 5% | NA | 0% | 7% |
| Dermatological toxicity | 10% | 5% | 33% | NA |
| Hepatic decompensation | 12% | NA | 0% | 7% |
| Death | 3% | 8% | 0% | 7% |
Table 3 Preliminary data on virological response during triple therapy in post-liver transplantation
| Verna et al[49] | Aqel et al[50] | McCashland et al[51] | Burton et al[52] | Kwo et al[53] | de Oliviera et al[54] | |
| Patients (n) | 101 | 23 | 10 | 12 | 7 | 6 |
| Regimen | ||||||
| BCV | 10 | 23 | 0 | 0 | 0 | 0 |
| TVL | 91 | 0 | 10 | 12 | 7 | 6 |
| Four-week lead-in phase | 96% | 100% | NA | 100% | 100% | NA |
| Fibrosis | ||||||
| F0–F2 | 58 | NA | 7 | 8 | 5 | NA |
| F3–F4 | 43 | NA | 3 | 4 | 2 | NA |
| Cholestatic hepatitis (n) | 10 | NA | NA | NA | 7 | NA |
| IS therapy | ||||||
| TAC | 23 | 0 | 0 | 0 | 2 | 6 |
| CSA | 67 | 23 | 10 | 12 | 5 | 0 |
| HCV genotype | 1 | 1 | 1 | 1 | 1 | 1 |
| HCV-RNA negative | ||||||
| Week 4 | 70% (64/92) | 43% (10/23) | 22% (2/9) | 92% (11/12) | 29% (2/7) | NA |
| Week 8 | 78% (61/78) | NA | NA | NA | 71% (5/7) | NA |
| Week 12 | 79% (68/86) | NA | 100% (3/3) | NA | NA | 33% (1/3) |
| Week 24 | NA | 17% (4/23) | 100% (1/1) | NA | NA | NA |
- Citation: Dall’Agata M, Gramenzi A, Biselli M, Bernardi M. Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents? World J Gastroenterol 2014; 20(28): 9253-9260
- URL: https://www.wjgnet.com/1007-9327/full/v20/i28/9253.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i28.9253